Comparative efficacy and safety of de-escalation, abbreviation, and standard potent P2Y12 inhibitor-based dual antiplatelet therapy strategies after acute coronary syndrome: a network meta-analysis
In brief
Two simplified antiplatelet strategies cut major bleeding by 57% after ACS
A network meta-analysis of seven randomized trials involving 20,673 patients found that switching to clopidogrel or shortening dual therapy and continuing a potent antiplatelet drug alone each reduced major bleeding by about 57% versus 12 months of standard therapy, without increasing major cardiovascular events. The strategies appeared comparable, but that comparison was indirect, so the best choice for individual patients remains unclear.
- Journal
- European heart journal open (Q1)
- Published
- 14 October 2026
- Study design
- Systematic review / meta-analysis of RCTs
- Evidence level
- Level 1, High (CEBM 1a)
- Authors
- Yee-Jen Wu, Hung-Ju Lin, Yi-Chen Chou, Yen-Hung Lin, Chi-Sheng Hung
- PMID
- 42948678
- DOI
- 10.1093/ehjopen/oeag173
Why clinicians should know about it
- Picked for Cardiology and Cardiovascular Medicine (paper of the day, 30 October 2026): Compares antiplatelet strategies after ACS using randomized trials
Abstract
AIMS: Potent P2Y12 inhibitor-based dual antiplatelet therapy (DAPT) is the default antiplatelet strategy after acute coronary syndrome (ACS), though de-escalation to clopidogrel-based DAPT and abbreviated DAPT followed by potent P2Y12 inhibitor monotherapy are increasingly adopted to mitigate bleeding risk. However, their relative efficacy and safety remain uncertain. METHODS AND RESULTS: Network meta-analyses of randomized controlled trials were performed to compare three guideline-endorsed strategies: (i) short-term potent P2Y12 inhibitor-based DAPT de-escalation to clopidogrel-based DAPT, (ii) abbreviated DAPT followed by potent P2Y12 inhibitor monotherapy, and (iii) standard 12-month potent P2Y12 inhibitor-based DAPT. The primary efficacy endpoint was major adverse cardiovascular events (MACE). Secondary efficacy endpoints included all-cause mortality, cardiovascular mortality, myocardial infarction, stent thrombosis, and stroke. The primary safety endpoint was major bleeding. The key net clinical endpoint was net adverse clinical events (NACE). PROSPERO (CRD420251144892) Seven randomized controlled trials involving 20 673 patients were included. Both the de-escalation and abbreviation strategies significantly reduced major bleeding (RR 0.43, 95% CI 0.25-0.74, P = 0.002; and RR 0.43, 95% CI 0.33-0.58, P < 0.001, respectively) and NACE (RR 0.54, 95% CI 0.41-0.70, P < 0.001; and RR 0.72, 95% CI 0.61-0.84, P < 0.001, respectively) without increasing MACE or other ischaemic outcomes. Indirect comparison indicated that de-escalation vs. abbreviation strategies demonstrated comparable MACE, NACE, and bleeding outcomes. CONCLUSION: Following ACS, both de-escalation to clopidogrel-based DAPT and abbreviated DAPT followed by potent P2Y12 inhibitor monotherapy effectively reduce bleeding risk without compromising ischaemic protection. Given that the only available comparison between the two simplified strategies was indirect and showed comparable MACE and NACE outcomes, further research is warranted to determine the optimal individualized approach.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.